Key Drivers
- Strong liquidity
- No revenue
- High burn
AIAI Summary
TYRA is no longer a cash-risk story but a funded, multi-catalyst clinical platform where the investment case now hinges on whether upcoming SURF302/BEACH301 readouts can validate dabogratinib across indications—because if the data disappoints, the enlarged optionality and extended runway won't prevent a sharp valuation reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •High burn
TYRA's balance sheet is strong with ample cash/investments and minimal debt, but ongoing revenue-free operations, heavy R&D spending, and persistent losses/free-cash-flow burn mean the stock's value still depends on financing strength rather than earnings power.
Price Behavior
Key Price Behavior Insights:
- •Higher low
- •Overhead supply
- •Support holding
TYRA has recovered sharply over the last month and is holding above $30, but the rebound remains fragile because sellers are still capping moves in the low-$32s.
Sharp rebound from about $25.4 on 2026-06-10 to above $30, then stalled near $32.1
Sentiment & News
Similar Companies in Healthcare
Other companies in the same sector with AI ratings